Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.
about
Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPaseThe role of experimental and computational structural approaches in 7TM drug discovery.Novel insights into G protein and G protein-coupled receptor signaling in cancerThe emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system.Allosteric sodium in class A GPCR signalingThe guanine exchange factor SWAP70 mediates vGPCR-induced endothelial plasticity.Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors.Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway.Disulfide Trapping for Modeling and Structure Determination of Receptor: Chemokine Complexes.GPCR activation: protonation and membrane potentialUS28, a Virally-Encoded GPCR as an Antiviral Target for Human Cytomegalovirus Infection.Chemokines, chemokine receptors and the gastrointestinal system.Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?PI3King the right partner: unique interactions and signaling by p110β.Viral manipulation of the host immune response.MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR.Hijacking GPCRs by viral pathogens and tumor.Allosteric Modulators of the Class A G Protein Coupled Receptors.Mechanisms of Regulation of the Chemokine-Receptor Network.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Intracellular trafficking of the human cytomegalovirus-encoded 7-trans-membrane protein homologs pUS27 and pUL78 during viral infection: a comparative analysis.YGLF motif in the Kaposi sarcoma herpes virus G-protein-coupled receptor adjusts NF-κB activation and paracrine actions.
P2860
Q28545016-407B9CAF-E0B5-4D73-BDFE-7D656ACB83C2Q30377191-6E37F62E-1FCA-43A0-90CE-7DFC23AA1B2BQ33612895-26BBCF03-C3F4-4DA5-9172-6CBBFDD79FABQ33799070-6E031AC4-2913-4633-AD3A-A492E31D349FQ33826984-363AA469-DF37-4FFD-9B80-8E8B0047200AQ33931569-863E0DD2-0670-4177-B3DA-87A94D1262DCQ35108526-9DEAE439-E1DB-43BF-A195-248EA8046F09Q35158385-2ABA1314-0EF6-4C43-80BD-037CA58F98C2Q36486893-C843C5A5-3F90-4DBE-8420-56C9A780ACA0Q36663709-AC074EF7-3722-43EB-9975-7CD57204531FQ36922998-F34ED8DC-D203-42E8-A7F4-985C2318E53AQ37551927-77228B5C-640B-43B1-A11B-9039CADFF643Q38109160-A94247FF-2B87-4C08-A756-6F8846DEC82EQ38180332-48F63B9B-299F-4357-B505-63F5966D8403Q38542387-01E1BDB9-5F71-4BF5-B3D9-EC9171479EF5Q38547642-902984A9-B76B-4D6C-A0C7-8C03BAF4D046Q38794695-37CDE623-DDF5-4B2E-B8B3-79A593370484Q38802773-CFC4AC75-EB1B-4633-9FEF-0627BCB411B0Q38847270-E13928C6-CAA4-4DB2-A25C-0BD3CFB6FC63Q39126530-05693E51-A829-4999-8104-DC8B02AA1FFFQ39433833-7D352316-5A1C-4DEC-9FB6-63FEAA286AAFQ41965432-F9A5A3C0-EB18-4741-8F3C-E9CA92302F60Q42251926-3182CC65-BDB2-44CA-8328-AFF8A078DB4C
P2860
Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Molecular mechanisms deployed ...... d receptors in human diseases.
@ast
Molecular mechanisms deployed ...... d receptors in human diseases.
@en
type
label
Molecular mechanisms deployed ...... d receptors in human diseases.
@ast
Molecular mechanisms deployed ...... d receptors in human diseases.
@en
prefLabel
Molecular mechanisms deployed ...... d receptors in human diseases.
@ast
Molecular mechanisms deployed ...... d receptors in human diseases.
@en
P2093
P2860
P1476
Molecular mechanisms deployed ...... d receptors in human diseases.
@en
P2093
Irina Kufareva
J Silvio Gutkind
Silvia Montaner
P2860
P304
P356
10.1146/ANNUREV-PHARMTOX-010510-100608
P577
2012-10-22T00:00:00Z